HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

Summary

Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (given one after another)-combined with local therapies (which treat cancer in a specific part of the body) and treatments that prevent cancer from spreading to the central nervous system (CNS; including the brain and spinal cord) can result in long-lasting remission and possibly cure some participants with HER2+ metastatic breast cancer.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Diagnostic Test
  Personalis NeXT Personal

  The use of this assay is expected to optimize treatment without introducing significant new risks or deviating from approved therapeutic protocols.

• Diagnostic Test
  Natera Signatera

  The use of this assay is expected to optimize treatment without introducing significant new risks or deviating from approved therapeutic protocols.

• Biological
  Trastuzumab deruxtecan-nxki

  T-DXd is a HER2-targeting antibody drug conjugate that consists of an anti-HER2 antibody.

Locations (7)